Corcept Therapeutics Incorporated (NASDAQ: CORT) stock closed at 23.8 per share at the end of the most recent trading day (a 2.37% change compared to the prior day closing price) with a volume of 1.31M shares and market capitalization of 2.53B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 236 people. Corcept Therapeutics Incorporated CEO is Joseph K. Belanoff.

The one-year performance of Corcept Therapeutics Incorporated stock is 2.56%, while year-to-date (YTD) performance is 20.2%. CORT stock has a five-year performance of 89.94%. Its 52-week range is between 15.825 and 25.68, which gives CORT stock a 52-week price range ratio of 80.92%

Corcept Therapeutics Incorporated currently has a PE ratio of 23.50, a price-to-book (PB) ratio of 5.58, a price-to-sale (PS) ratio of 5.75, a price to cashflow ratio of 14.70, a PEG ratio of 2.32, a ROA of 22.60%, a ROC of 24.16% and a ROE of 25.13%. The company’s profit margin is 29.38%, its EBITDA margin is 35.40%, and its revenue ttm is $380.23 Million , which makes it $3.58 revenue per share.

Of the last four earnings reports from Corcept Therapeutics Incorporated, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.21 for the next earnings report. Corcept Therapeutics Incorporated’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Corcept Therapeutics Incorporated is Moderate Buy (1.83), with a target price of $26.83, which is +12.73% compared to the current price. The earnings rating for Corcept Therapeutics Incorporated stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Corcept Therapeutics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Corcept Therapeutics Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 17.38, ATR14 : 0.84, CCI20 : 257.14, Chaikin Money Flow : 0.23, MACD : 0.49, Money Flow Index : 72.56, ROC : 11.11, RSI : 69.91, STOCH (14,3) : 99.18, STOCH RSI : 1.00, UO : 67.04, Williams %R : -0.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Corcept Therapeutics Incorporated in the last 12-months were: Daniel N. Swisher (Option Excercise at a value of $49 125), Daniel N. Swisher (Sold 7 500 shares of value $162 741 ), David L. Mahoney (Option Excercise at a value of $121 500), G. Charles Robb (Option Excercise at a value of $799 999), G. Charles Robb (Sold 102 500 shares of value $2 122 747 ), Hazel Hunt (Option Excercise at a value of $277 300), James N. Wilson (Option Excercise at a value of $624 000), Sean Maduck (Option Excercise at a value of $538 300), Sean Maduck (Sold 150 000 shares of value $3 203 270 )